An experimentally validated network of nine haematopoietic transcription factors reveals mechanisms of cell state stability

  1. Judith Schütte
  2. Huange Wang
  3. Stella Antoniou
  4. Andrew Jarratt
  5. Nicola K Wilson
  6. Joey Riepsaame
  7. Fernando J Calero-Nieto
  8. Victoria Moignard
  9. Silvia Basilico
  10. Sarah J Kinston
  11. Rebecca L Hannah
  12. Mun Chiang Chan
  13. Sylvia T Nürnberg
  14. Willem H Ouwehand
  15. Nicola Bonzanni
  16. Marella FTR de Bruijn
  17. Berthold Göttgens  Is a corresponding author
  1. University Hospital Essen, Germany
  2. University of Cambridge, United Kingdom
  3. University of Oxford, United Kingdom
  4. Walter and Eliza Hall Institute of Medical Research, Australia
  5. University of Pennsylvania, United States
  6. VU University Amsterdam, Netherlands

Abstract

Transcription factor (TF) networks determine cell type identity by establishing and maintaining lineage-specific expression profiles, yet reconstruction of mammalian regulatory network models has been hampered by a lack of comprehensive functional validation of regulatory interactions. Here, we report comprehensive ChIP-Seq, transgenic and reporter gene experimental data that have allowed us to construct an experimentally validated regulatory network model for haematopoietic stem/progenitor cells (HSPCs). Model simulation coupled with subsequent experimental validation using single cell expression profiling revealed potential mechanisms for cell state stabilisation, and also how a leukemogenic TF fusion protein perturbs key HSPC regulators. The approach presented here should help to improve our understanding of both normal physiological and disease processes.

Article and author information

Author details

  1. Judith Schütte

    Department of Haematology, University Hospital Essen, Essen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Huange Wang

    Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Stella Antoniou

    MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Andrew Jarratt

    Division of Molecular Medicine, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
    Competing interests
    The authors declare that no competing interests exist.
  5. Nicola K Wilson

    Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Joey Riepsaame

    MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Fernando J Calero-Nieto

    Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Victoria Moignard

    Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Silvia Basilico

    Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Sarah J Kinston

    Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Rebecca L Hannah

    Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Mun Chiang Chan

    MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Sylvia T Nürnberg

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Willem H Ouwehand

    Department of Haematology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Nicola Bonzanni

    IBIVU Centre for Integrative Bioinformatics, VU University Amsterdam, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  16. Marella FTR de Bruijn

    MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Berthold Göttgens

    Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom
    For correspondence
    bg200@cam.ac.uk
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Amy J Wagers, Harvard University, United States

Ethics

Animal experimentation: All mice were housed in microisolator cages and provided continuously with sterile food, water, and bedding. All mice were kept in specified pathogen-free conditions, and all procedures were performed according to the United Kingdom Home Office regulations under project licence 70/8406

Version history

  1. Received: September 9, 2015
  2. Accepted: February 12, 2016
  3. Accepted Manuscript published: February 22, 2016 (version 1)
  4. Version of Record published: March 10, 2016 (version 2)

Copyright

© 2016, Schütte et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,675
    views
  • 865
    downloads
  • 60
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Judith Schütte
  2. Huange Wang
  3. Stella Antoniou
  4. Andrew Jarratt
  5. Nicola K Wilson
  6. Joey Riepsaame
  7. Fernando J Calero-Nieto
  8. Victoria Moignard
  9. Silvia Basilico
  10. Sarah J Kinston
  11. Rebecca L Hannah
  12. Mun Chiang Chan
  13. Sylvia T Nürnberg
  14. Willem H Ouwehand
  15. Nicola Bonzanni
  16. Marella FTR de Bruijn
  17. Berthold Göttgens
(2016)
An experimentally validated network of nine haematopoietic transcription factors reveals mechanisms of cell state stability
eLife 5:e11469.
https://doi.org/10.7554/eLife.11469

Share this article

https://doi.org/10.7554/eLife.11469

Further reading

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology
    Richard Sejour, Janet Leatherwood ... Bruce Futcher
    Research Article

    Previously, Tuller et al. found that the first 30–50 codons of the genes of yeast and other eukaryotes are slightly enriched for rare codons. They argued that this slowed translation, and was adaptive because it queued ribosomes to prevent collisions. Today, the translational speeds of different codons are known, and indeed rare codons are translated slowly. We re-examined this 5’ slow translation ‘ramp.’ We confirm that 5’ regions are slightly enriched for rare codons; in addition, they are depleted for downstream Start codons (which are fast), with both effects contributing to slow 5’ translation. However, we also find that the 5’ (and 3’) ends of yeast genes are poorly conserved in evolution, suggesting that they are unstable and turnover relatively rapidly. When a new 5’ end forms de novo, it is likely to include codons that would otherwise be rare. Because evolution has had a relatively short time to select against these codons, 5’ ends are typically slightly enriched for rare, slow codons. Opposite to the expectation of Tuller et al., we show by direct experiment that genes with slowly translated codons at the 5’ end are expressed relatively poorly, and that substituting faster synonymous codons improves expression. Direct experiment shows that slow codons do not prevent downstream ribosome collisions. Further informatic studies suggest that for natural genes, slow 5’ ends are correlated with poor gene expression, opposite to the expectation of Tuller et al. Thus, we conclude that slow 5’ translation is a ‘spandrel’--a non-adaptive consequence of something else, in this case, the turnover of 5’ ends in evolution, and it does not improve translation.

    1. Computational and Systems Biology
    Hedi Chen, Xiaoyu Fan ... Boxue Tian
    Research Article

    Accurate prediction of the structurally diverse complementarity determining region heavy chain 3 (CDR-H3) loop structure remains a primary and long-standing challenge for antibody modeling. Here, we present the H3-OPT toolkit for predicting the 3D structures of monoclonal antibodies and nanobodies. H3-OPT combines the strengths of AlphaFold2 with a pre-trained protein language model and provides a 2.24 Å average RMSD between predicted and experimentally determined CDR-H3 loops, thus outperforming other current computational methods in our non-redundant high-quality dataset. The model was validated by experimentally solving three structures of anti-VEGF nanobodies predicted by H3-OPT. We examined the potential applications of H3-OPT through analyzing antibody surface properties and antibody–antigen interactions. This structural prediction tool can be used to optimize antibody–antigen binding and engineer therapeutic antibodies with biophysical properties for specialized drug administration route.